IDVYNSO Drug Patent Profile

When do Idvynso patents expire, and when can generic versions of Idvynso launch?

Idvynso is a drug marketed by MSD and is included in one NDA.

The generic ingredient in IDVYNSO is doravirine; islatravir. One supplier is listed for this compound. Additional details are available on the doravirine; islatravir profile page.

Summary for IDVYNSO

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in IDVYNSO?	IDVYNSO excipients list
DailyMed Link:	IDVYNSO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IDVYNSO

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

216964

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for IDVYNSO

Drug Class	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for IDVYNSO

IDVYNSO is protected by zero US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd	IDVYNSO	doravirine; islatravir	TABLET;ORAL	216964-001	Apr 20, 2026		RX	Yes	Yes

Last updated: June 6, 2026

IDVYNSO market dynamics and financial trajectory: what to know on sales, competition, and IP risk

IDVYNSO market dynamics and financial trajectory cannot be analyzed from verifiable inputs in the prompt. No drug details are provided (active ingredient, indication, manufacturer, FDA approval/Orange Book status, pricing, sales history, distribution model, or payer coverage). With those missing, a complete, accurate market-and-finance profile is not possible under this task’s constraints.

Key Takeaways

• IDVYNSO market dynamics and financial trajectory cannot be produced without verifiable drug identity and commercial data.
• Any attempt to infer the product would risk material inaccuracies on sales, exclusivity, generic/biosimilar entry timing, and litigation.

FAQs

1. What determines IDVYNSO pricing power across commercial and government payers?
2. How do patent and exclusivity timelines shape IDVYNSO revenue risk?
3. What role do formulary tiers play in IDVYNSO net sales trajectory?
4. How does channel mix (buy-and-bill vs dispensing) affect IDVYNSO cash flow?
5. When do generic entry signals typically appear for drugs like IDVYNSO?